




>>Entry Name: Gangliosides



Related CAS Registry Numbers(s): 19553-76-5 19600-01-2 54827-14-4 59247-13-1 62010-37-1 69345-49-9 71012-19-6 85305-87-9 85305-88-0 89678-50-2

General Statement: A large class of glycosphingolipids composed of hexoses, Sphingosine, fatty acids and sialic acids. The differences between the gangliosides are mainly in the carbohydrate moieties. Four major gangliosides referred to as G_{M1} (illus.), D_{D1a} , G_{D1b} , G_{T1b}

Biological Source: Found in the CNS and widely distributed in other tissues

Use/Importance: Gangliosides are the main cause of cell surface negative charge. They are also thought to be involved in many different cell functions e.g. metabolism, growth and malignant transformation. A monoganglioside prep. has been used in the treatment of cerebrovascular disorders

>>Variant: Ganglioside G_{M1}

Synonym(s): Ganglioside G_1 . Siagoside. Sygen

CAS Registry Number: 37758-47-7

Molecular Formula: $C_{73}H_{131}N_3O_{31}$

Molecular Weight: 1546.839

Accurate Mass: 1545.876662

Percentage Composition: C 56.68%; H 8.54%; N 2.72%; O 32.06%

Biological Source: Isol. from bovine brain. Constit. of mammalian vertebrate cell membranes. Particularly abundant in the central and peripheral nervous systems

Biological Use/Importance: Used in the treatment of peripheral neuropathies, cerebrovascular disorders and spinal cord injury. Positive effects still need to be confirmed. Now used in the treatment of Parkinson's disease

References:

- Kuhn, R. *et al.*, *Chem. Ber.*, 1963, **96**, 866-880, (*isol, struct*)
Klenk, E., *Prog. Chem. Fats Other Lipids*, 1970, **10**, 411
Gigg, R.H., *Rodd's Chem. Carbon Compd. (3rd edn.)*, 1976, **1E**, 394
Sillerud, L.O. *et al.*, *Carbohydr. Res.*, 1983, **113**, 173-188, (*cmr*)
Fishman, P.H., *Chem. Phys. Lipids*, 1986, **42**, 137-151, (*rev, props*)
Sonnino, S. *et al.*, *Adv. Exp. Med. Biol.*, 1988, **228**, 437, (*rev*)
Jack, D.B., *J. Clin. Pharm. Ther.*, 1990, **15**, 233, (*rev*)
Skaper, S.D. *et al.*, *Adv. Exp. Med. Biol.*, 1991, **296**, 257-266, (*rev*)
Rost, K.L. *et al.*, *Clin. Pharmacol. Ther. (St. Louis)*, 1991, **50**, 141-149, (*pharmacokinet*)
Rodden, F.A. *et al.*, *J. Neurosurg.*, 1991, **74**, 606, (*rev*)
Sandhoff, K. *et al.*, *Adv. Lipid Res.*, 1993, **26**, 119, (*rev, metab, biosynth*)
Walker, J.B. *et al.*, *Neurosci. Lett.*, 1993, **161**, 174-178, (*bibl*)
Nobile-Orazio, E. *et al.*, *Drugs*, 1994, **47**, 576-585, (*rev, struct, pharmacol, tox*)
Schneider, J.S. *et al.*, *Neurology*, 1995, **45**, 1149-1154, (*anti-Parkinsonian pilot study*)
Martindale, *The Extra Pharmacopoeia*, 31st edn., Pharmaceutical Press, 1996, 1708
Duclos, R.I., *Carbohydr. Res.*, 2000, **238**, 489-507, (*synth*)
Bhattacharya, S.K. *et al.*, *J.O.C.*, 2000, **65**, 144-151, (*synth, GM1*)